Michele T. Yip-Schneider
Department of Surgery
Indiana University School of Medicine
Indianapolis
USA
Name/email consistency: high
- Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Yip-Schneider, M.T., Wu, H., Njoku, V., Ralstin, M., Holcomb, B., Crooks, P.A., Neelakantan, S., Sweeney, C.J., Schmidt, C.M. Pancreas (2008)
- Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Yip-Schneider, M.T., Wu, H., Ralstin, M., Yiannoutsos, C., Crooks, P.A., Neelakantan, S., Noble, S., Nakshatri, H., Sweeney, C.J., Schmidt, C.M. Mol. Cancer Ther. (2007)
- Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Yip-Schneider, M.T., Nakshatri, H., Sweeney, C.J., Marshall, M.S., Wiebke, E.A., Schmidt, C.M. Mol. Cancer Ther. (2005)
- MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Yip-Schneider, M.T., Schmidt, C.M. Pancreas (2003)
- Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Yip-Schneider, M.T., Lin, A., Marshall, M.S. Biochem. Biophys. Res. Commun. (2001)
- Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Yip-Schneider, M.T., Barnard, D.S., Billings, S.D., Cheng, L., Heilman, D.K., Lin, A., Marshall, S.J., Crowell, P.L., Marshall, M.S., Sweeney, C.J. Carcinogenesis (2000)









